JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HARBISON, R. D.
Right arrow Articles by BECKER, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HARBISON, R. D.
Right arrow Articles by BECKER, B. A.
Journal of Pharmacology And Experimental Therapeutics, Vol. 175, Issue 2, 283-288, 1970
Copyright © 1970 by American Society for Pharmacology and Experimental Therapeutics


EFFECT OF PHENOBARBITAL AND SKF 525A PRETREATMENT ON DIPHENYLHYDANTOIN TERATOGENICITY IN MICE

RAYMOND D. HARBISON 1 and BERNARD A. BECKER 1

1 Oakdale Toxicology Center, Department of Pharmacology, College of Medicine, University of Iowa, Iowa City, Iowa

Diphenylhydantoin (DPH) treatment of primigravid Swiss-Webster mice is teratogenic and produces statistically significant increases in in utero deaths. Phenobarbital pretreatment significantly increases and 2-diethylaminoethyl- 2,2-diphenylvalerate hydrochloride (SKF 525A) pretreatment significantly decreases the plasma disappearance of DPH. These experiments indicate that phenobarbital probably stimulates and SKF 525A probably inhibits the metabolism of DPH in mice. Phenobarbital pretreatment significantly reduces and SKF 525A pretreatment significantly increases the incidence of DPH-induced fetal resorptions. Phenobarbital pretreatment does not antagonize the DPH-induced reduction of fetal body size, but SKF 525A pretreatment potentiates the response. Phenobarbital pretreatment antagonizes and SKF 525A pretreatment potentiates the DPH-induced orofacial and skeletal anomalies. These data indicate that under conditions which apparently stimulate DPH metabolism, diphenylhydantoin-induced teratogenicity is decreased; when conditions favor inhibition of DPH metabolism, teratogenicity is enhanced.

Submitted on March 30, 1970
Accepted on July 27, 1970




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
L. M. Winn, P. M. Kim, and P. G. Wells
Investigation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone for In Vivo and In Vitro Murine Embryopathy and Embryonic ras Mutations
J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1128 - 1135.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1970 by the American Society for Pharmacology and Experimental Therapeutics.